BrainsWay Q3 revenue climbs 34% to $18.1m as SWIFT coverage reaches 70m US lives
The Deep TMS maker reported operating income of $2.6m and 130 systems shipped, and expects full-year 2026 results at the upper end of its guidance.
BrainsWay reported third-quarter 2026 revenue of $18.1 million on 10 November, a 34% increase on the same period a year earlier, according to the headline of its results announcement. Operating income was $2.6 million, which the company said was more than double the prior-year figure.
The company shipped 130 Deep TMS systems during the quarter. Deep TMS is BrainsWay's transcranial magnetic stimulation technology, which is delivered through devices placed in clinics.
BrainsWay also said that payer policies covering its SWIFT accelerated Deep TMS protocol now extend to more than 70 million lives in the United States. The company did not give further detail in the material available on which payers are involved or on the terms of coverage.
Looking ahead, BrainsWay expects full-year 2026 results at the upper end of its guidance, with potential to modestly exceed it. The full text of the release, including the guidance figures themselves, was not available for this report.
Why it matters
- Market-access teams in neuromodulation should note that payer policies for accelerated TMS protocols such as SWIFT are expanding, with reported coverage now above 70 million US lives.
- Coverage decisions are policy-specific, so teams should check individual payer criteria rather than rely on the aggregate lives figure.
- Device makers and clinics tracking the sector can read the 130-system shipment figure as one indicator of installed-base growth.
Company's press release (SEC filing): Brainsway Ltd. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
